NLRP3 and ischemic stroke: For example, recent studies have documented how mir-223 may represent a new therapeutic expedient in case of ischemic stroke as it binds to a conserved site in the 3 UTR of the NLRP3, inactivates the latter, and inhibits the release of IL-1β.